Se desexas distinguir vos teus produtos, servizos ou ambos os dous doutra empresa, é posible que necesites unha marca ou nome comercial. Descobre que son, en que consiste ou seu procedemento de rexistro e que implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Se tes un novo dispositivo, produto ou procedemento que resolva un problema técnico ou teña unha vantaxe práctica, existen distintas formas de protexelo en España e noutros países. Descobre como facelo.
A túa innovación reside na estética, a ornamentación ou a aparencia do teu produto? Protéxea mediante un deseño industrial. Descobre que dereitos confire ou rexistro e como realizar a tramitación.
As indicacións xeográficas protexen o nome dun produto orixinario dunha zona xeográfica, á cal lle debe unha determinada calidade, reputación ou outra característica. Descobre que son, en que consiste o seu procedemento de rexistro e que beneficios conceden.
As patentes publicadas en todo ou mundo son unha valiosa fonte de información científica, técnica e comercial.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ése emprendedor/a ou unha empresa e queres potenciar e mellorar a rendibilidade do teu negocio protexendo de forma adecuada vos activos intangibles dá túa organización, neste espazo atoparás ou necesario.
65
resultados
Última actualización
29/10/2026 [08:22:00]
Resumen de: EP4831178A1
The present invention provides a novel Kv1.3 channel (or Kv1.3) inhibitor, which can be used for preventing and/or treating Kv1.3 channel (or Kv1.3)-related diseases, including immune and inflammatory diseases, such as multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, rheumatoid arthritis, type 1 diabetes, psoriasis and asthma, spondylitis and periodontitis; and obesity, type 2 diabetes, renal fibrosis, Alzheimer's disease, and ischemic stroke.
Resumen de: EP4830784A2
Changes in Reelin levels as well as Reelin signaling alter cognitive function. This can be accomplished by administering a therapeutically effective amount of a repeat fragment of Reelin, or a construct formed from fragment repeats of Reelin to a patient or subject. Changes to Reelin levels can be used to treat various neurodegenerative diseases, neuronal insults, or stroke, such as fragile X syndrome, William's syndrome, Rett syndrome, Down's syndrome, Angelman syndrome, autism, ischemia, hypoxia, Alzheimer's disease, and schizophrenia. Reelin can also be used to alter dendritic spine density, diminished long-term potentiation, and diminished synaptic plasticity and associative learning deficits. Constructs formed from repeat region 3 of full length Reelin and repeat region 5 of full length Reelin, or repeat region 3 of full length Reelin and repeat region 6 of full length Reelin have been found particularly useful.
Resumen de: WO2025131275A1
The present invention relates to pharmaceutical compositions and medicaments comprising the compound of formula (I); or a stereoisomer, tautomer, pharmaceutically usable solvate or salt thereof, and dosage regimens for the administration thereof to human patients.
Resumen de: EP4830706A1
0001 The present invention relates to use of a novel compound for preventing, alleviating, or treating Alzheimer's disease, and the novel compound exhibits an inhibitory effect on tau protein aggregation. In addition, it was identified that presenilin 1 was reduced by treatment using the novel compound. Therefore, the novel compound can be effectively used in the development of a therapeutic agent for Alzheimer's disease.
Resumen de: WO2025134078A1
The present invention relates to the compounds of formula (I), or an isotopic form, a stereoisomer, or pharmaceutically acceptable salt thereof as muscarinic M4 receptor positive allosteric modulators (M4 PAMs). The present invention also relates to pharmaceutical compositions comprising such compounds, chemical processes of preparation of such compounds and use of such compounds in the treatment of psychiatric and/or neurological disorders.
Resumen de: WO2025134150A1
This present invention relates to small molecules which are biphenyl pyridine rigid compounds with polycyclic heterocycles therapeutically useful as immune modulators These compounds disrupt the PD-1/PD-L1 checkpoint pathway and may also disrupt one or more related checkpoint pathways. These compounds are useful in treating, preventing or ameliorating disorders such as cancer or infections.
Resumen de: WO2025137077A1
Compositions and methods are disclosed herein for the treatment of Alzheimer's disease with allogeneic mesenchymal stem cells. The methods of treatment involve the administration of a composition of allogeneic mesenchymal stem cells to a subject in need thereof, wherein the efficacy of the treatment methods can be determined through the measurement of specific biomarkers and improved cognitive function and/or quality of life.
Resumen de: AU2024434669A1
The present invention belongs to the technical field of biomedicine, and relates to a class of dexborneol or fenchyl alcohol ester derivatives of 2-hydroxynicotinic acid, and pharmaceutical uses thereof. The structural general formula of the derivatives is (1), R1 being selected from -H, -Cl, a hydrocarbon group having 1-8 carbon atoms, -CF3, -CF2H, -CN, -SCH3, -OH, -CHO, -CH2OH, -CH2NH2, -COOH, halogenated phenyl, or -NR4R5; R4, R5 are independently selected from -H or -CH3; R2 is selected from -H, an alkyl group having 1-6 carbon atoms, an acyl group having 2-7 carbon atoms, or a carbamoyl group; R 3 is selected from formula (a) or formula (b); X is selected from -CH= or -N=. The derivatives have good inflammation-inhibiting effects, and at high concentrations, they exhibit low cytotoxicity and are safer. The derivatives can be used for preparing a drug for treating inflammation and inflammation-related diseases such as stroke, neuropathic pain, depression and Alzheimer's disease.
Resumen de: US20260325464A1
The present invention discloses a composition comprising compounds of Formula I for use in modulating and maintaining water homeostasis in the brain by modulating the expression of aquaporins. More specifically, the invention discloses the use of Gingerenone A in the management of neurodegenerative disorders, specifically Alzheimer's disease and Parkinson's disease by modulating aquaporin expression.
Resumen de: US20260327271A1
Recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment are described. The fusion proteins may be administered to patients having a disease or a disorder with the intention of mitigating and/or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and/or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in amyotrophic lateral sclerosis (ALS) patients associated with the condition or disease. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, for example, by a decrease or elimination of symptoms associated with ALS, and/or by a decrease in the duration of such symptoms.
Resumen de: US20260327703A1
0000 The present invention relates to microRNAs for use in diagnostic methods for diagnosing and/or for distinguishing by diagnosis Alzheimer's disease (AD), Frontotemporal Dementia (FTD), and possibly other tauopathies, and/or for measuring therapeutic effect of a treatment of FTD or AD.
Resumen de: US20260325476A1
0000 Disclosed are methods for inhibiting the progression of neurodegenerative disease. The methods include administering to a patient suffering from such a disease a composition comprising either deuterated linoleic acid or an ester thereof.
Resumen de: US20260327296A1
0000 The present invention is in the field of transactive response DNA binding protein with a molecular weight of 43 kDa (TARDB or also TDP-43). The invention relates to TDP-43 specific binding molecules, in particular to anti-TDP-43 antibodies or an antigen-binding fragment or a derivative thereof and uses thereof. The present invention provides means and methods to diagnose, prevent, alleviate and/or treat a disease, disorder and/or abnormality associated with TDP-43 aggregates including but not limited to Frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), Parkinson's disease (PD), Chronic Traumatic Encelopathy (CTE), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Resumen de: US20260325453A1
0000 Polydopamine-coated nanoparticles are presented as a novel composition for intracranial delivery, designed to absorb UV photons and mitigate neuroinflammation in brain tissue. These nanoparticles feature a core that includes materials such as silica, gold, iron oxide, or polymeric micelles and are encapsulated within a polydopamine shell. Additionally, biologically active agents can be incorporated to enhance neuroprotection. Methods are provided for treating neurodegenerative diseases (e.g., Parkinson's, Huntington's, ALS, Alzheimer's) or improving glioblastoma therapy by administering the polydopamine-coated nanoparticles directly to affected brain regions via intracerebral injection, intrathecal infusion, or convection-enhanced delivery. Furthermore, the polydopamine-coated nanoparticles hold potential for pharmaceutical applications in developing medicaments targeting neuroinflammation and UV photon absorption within the central nervous system.
Resumen de: WO2026220933A1
Provided is a pharmaceutical composition that has fewer side effects and that makes it possible to obtain an effect of preventing or treating Parkinson's disease A pharmaceutical composition for preventing or treating Parkinson's disease according to an embodiment of the present invention contains a nucleic acid that inhibits the expression of Rap1GAP.
Resumen de: WO2026222314A1
The disclosure is directed, in part, to methods of treating a patient suffering from a neurodegenerative disease, e.g., Parkinson's disease, comprising administering to the patient and effective amount of a TYK2 inhibitor. In some embodiments, the patient has elevated myxovirus resistance protein 1 (MX1) gene or protein expression.
Resumen de: WO2026220298A1
Provided for are prodrugs of doxycycline. The prodrugs may be advantageously administered for the treatment of disease, including neurological and neurodegenerative diseases or disorders. Doxycycline prodrugs may have reduced antibiotic activity compared to doxycycline for improved pharmacological properties. Also provided for are methods of treating neurodegenerative diseases such as Parkinson's disease or an alpha synucleinopathy with the doxycycline prodrugs and pharmaceutical compositions thereof.
Resumen de: US20260325548A1
A method of reducing neuroinflammation, tau accumulation, tau phosphorylation, and/or corticosterone secretion to treat or prevent Alzheimer's disease or related dementias, depression, and/or anxiety in patients previously infected with a respiratory virus such as SARS CoV2 is presented. Glucocorticoid receptor antagonists such as mifepristone and nanodendriplexes comprising RNA interference agents targeting FKBP5, IFI16, or a combination thereof exhibit efficacy in reducing abnormal tau accumulation and neuroinflammation in Cov-2-infected patients to reduce neurological symptoms associated with infection.
Resumen de: US20260325583A1
0000 Disclosed are methods of treating amyotrophic lateral sclerosis in a subject by administering a therapeutic MSC secretome product made by a method comprising culturing bone marrow-derived MSCs under conditions that include oxygen tension below 5% and a culture media with a pH below 7.
Resumen de: US20260325670A1
0000 The invention provides a composition for delivering an active pharmaceutical ingredient (API) and/or active nutraceutical ingredient (ANI) to the basal ganglia of a subject in need thereof comprising a plurality of nanoparticles surface decorated with caffeine, wherein the nanoparticles comprising: at least one API or ANI, at least one emulsifier, at least one emulsifier stabilizer, at least one water miscible solvent, and at least one solid lipid matrix core; and a pharmaceutically or nutraceutically acceptable carrier. The invention further provides methods for delivering active ingredients to the to the basal ganglia of a subject in need thereof and methods for treating Parkinson's disease.
Resumen de: US20260327279A1
0000 A HIP/PAP protein, or a derivative thereof, is provided for the treatment and prevention cognition conditions. In particular the HIP/PAP protein, or a derivative thereof is for the treatment of a cognitive disorder associated with anxiety disorder(s) in an individual in need thereof as well as for improving cognition in an individual affected by a neurological disorder associated with anxiety disorder(s). The HIP/PAP protein, or a derivative thereof is also alleviating cognitive deficit in an individual affected by a disorder selected from Obsessive-compulsive disorder, Attention deficit disorder, Dementia with Lewy bodies disease, Early onset dementia, Epilepsy-related cognitive dysfunction, Fronto-temporal dementia, Posterior cortical atrophy, Huntington's disease (HD), Parkinson's disease, bipolar disorder, substance abuse, attention deficit disorders, psychotic disorders and a sars-cov-2 infection, and also in the prevention and/or treatment of diet induced cognitive and anxiety deficits in an individual in need thereof, and in particular high fat diet induced cognitive and anxiety deficits.
Resumen de: US20260325575A1
Provided is a use of borate derivatives in the treatment of amyotrophic lateral sclerosis (ALS), which is a neurodegenerative disease. More particularly, the development and administration of pharmaceutical formulations including at least one borate derivative is provided. The borate derivatives are one or a mixture of compounds sodium pentaborate pentahydrate (NaB; NaB5O8·5H2O) or sodium perborate tetrahydrate (SPT; NaBO3·4H2O).
Resumen de: WO2025128873A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Resumen de: WO2025128848A1
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a neurodegenerative disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).
Nº publicación: EP4824066A1 21/10/2026
Solicitante:
MERCK SHARP & DOHME LLC [US]
Merck Sharp & Dohme LLC
Resumen de: WO2025128781A1
Novel compounds of Formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of NLRP3 and may be useful in the treatment, prevention, management, amelioration, control and suppression of diseases mediated by NLPR3. The compounds of the present invention may be useful in the treatment, prevention or management of diseases, disorders and conditions mediated by NLRP3 such as, but not limited to, obesity, gout, pseudogout, CAPS, NASH, MASH, fibrosis, heart failure, idiopathic pericarditis, atopic dermatitis, inflammatory bowel disease, Alzheimer's Disease, Parkinson's Disease, dementia with Lewy bodies (DLB), and traumatic brain injury.
BOPI
Sede Electrónica
